Evidence map›Paper›PMID 20826636›Full record

ArticleJournal of clinical microbiology2010

Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain.

R Cisterna, G Ezpeleta, O Telleria, J Guinea, B Regueiro, J Garcia-Rodríguez, J Esperalba, Spanish Candidemia Surveillance Group

RetractedErratum issuedAbstract readRetracted Publication
In one paragraph

Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 71 citations in OpenAlex.

  1. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2012
    Trial
  2. Article
  3. Article
  4. Biomarkers of fungal infection: Expert opinion on the current situation.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020
    Article
  5. Impact of empirical treatment with antifungal agents on survival of patients with candidemia.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019
    Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Epidemiology and risk factors for invasive candidiasis.Therapeutics and clinical risk management · 2014
    Review
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Insights into Candida tropicalis nosocomial infections and virulence factors.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012
    Review
  18. Article
  19. Article
  20. Epidemiology and antifungal resistance in invasive candidiasis.European journal of medical research · 2011
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

R CisternaBasurto Hospital, Clinical Microbiology and Infection Control Department, Bilbao, Spain. ramon.cisternacancer@osakidetza.net
G Ezpeleta
O Telleria
J Guinea
B Regueiro
J Garcia-Rodríguez
J Esperalba
Spanish Candidemia Surveillance Group
Hospital de Basurto · ESComplejo Hospitalario Universitario de Santiago · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario La Paz · ESHospital Universitario Puerta de Hierro Majadahonda · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Candidemia studies have documented geographic differences in rates and epidemiology, underscoring the need for surveillance to monitor trends. We conducted prospective candidemia surveillance in Spain to assess the incidence, species distribution, frequency of antifungal resistance, and risk factors for acquiring a Candida infection. Prospective laboratory-based surveillance was conducted from June 2008 to June 2009 in 40 medical centers located around the country. A case of candidemia was defined as the isolation of a Candida species from a blood culture. Incidence rates were calculated per 1,000 admissions. Antifungal susceptibility tests were performed by using broth microdilution assay according to the guidelines of the Clinical and Laboratory Standards Institute. We detected 984 cases, for an overall incidence of 1.09 cases per 1,000 admissions. The crude mortality was 20.20%. Candida albicans was the most common species (49.08%), followed by C. parapsilosis (20.73%), C. glabrata (13.61%), and C. tropicalis (10.77%). Overall, decreased susceptibility to fluconazole occurred in 69 (7.01%) incident isolates. Antifungal resistance was rare, and a moderate linear correlation between fluconazole and voriconazole MICs was observed. This is the largest multicenter candidemia study conducted to date and shows the substantial morbidity and mortality of candidemia in Spain.

Indexed as

AdolescentAdultAgedAged, 80 and overAntifungal AgentsCandidaCandidiasisChildChild, PreschoolDrug Resistance, FungalFemaleFungemiaHospitalsHumansIncidenceInfantAntifungal Agents

Identifiers

PMID20826636
PMCPMC3020865
OpenAlexW2102194853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.